Hana to start new phase 1/2 Talvesta trial in Q4

By Elaine Rigoli

Tampa, Fla., Sept. 18 - Hana Biosciences, Inc. said it will be initiating a phase 1/2 trial in solid tumors and advanced gastric cancer using a 21-day dosing schedule to enhance the therapeutic index of Talvesta (talotrexin) for injection.

Talvesta is currently in three separate clinical trials in hematological and solid tumors including a phase 1/2 study in acute lymphoblastic leukemia, phase 1/2 in non-small cell lung cancer and a phase 1 trial in solid tumors.

Hana is a South San Francisco, Calif.-based biopharmaceutical company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.